此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Long-term Iron Absorption and Loss in Women

2026年9月28日 更新者:Tippawan Pongcharoen、Mahidol University

Long-term Iron Absorption and Loss in Overweight/Obese Thai Middle-aged Women

Obese people typically have chronic low-grade inflammation. Based on short-term studies, this inflammation could affect the absorption, utilization, storage, and mobilization of iron, and individuals with inflammation might develop iron deficiency (ID) and anemia when inadequacy of iron intake is presented. The double burden of malnutrition is nowadays emerging as a major public health concern in many countries, including Thailand. Understanding the association of chronic inflammation among people with overweight or obesity (OW/OB) with long-term iron absorption and loss is important for developing appropriate policies and programs to promote iron balance and, consequently, optimal iron status and health outcomes. Since previous reports among Thai women showed a high prevalence of OW/OB and anemia, this study will be conducted to determine the long-term iron absorption and loss among OW/OB free-living women using the iron isotope dilution method.

研究概览

地位

招聘中

详细说明

  1. Research Objective To study iron absorption, loss, and long-term iron gain in overweight or obese middle-aged Thai women compared with normal-weight middle-aged Thai women.
  2. Research Methodology 2.1 Study design: This study is a longitudinal study comparing long-term iron absorption and loss between overweight or obese middle-aged Thai women and normal-weight middle-aged Thai women.

2.2 Study population: The study population consists of 64 women aged 40-50 years, divided into two groups: 32 overweight or obese women, and 32 normal-weight women.

2.3 Research Procedures 2.3.1 Before data collection: The research protocol is submitted for approval to the Central Institutional Review Board, Mahidol University. All data collectors will be trained prior to fieldwork. Upon receiving ethical approval, recruitment posters will be used to invite participants.

Screening process:

  1. Interested individuals meeting preliminary eligibility criteria will be informed about study details, sign informed consent, and schedule the first visit for screening and blood collection.

  2. Visit 1 (Screening):

    • Collect demographic and health history, measure weight, height, and body composition.
    • Collect 5 mL blood sample for Hb, SF, CRP, AGP, and hemoglobin typing.
    • Perform urine pregnancy test.
    • Administer one 400 mg albendazole tablet to prevent parasitic infection.

Iron isotope administration and follow-up:

2.3.2 Eligible participants will return within 1-2 weeks for the second visit.

Visit 2 (Month 0; M0):

Participants will consume a 15 mg ⁵⁷Fe isotope solution followed by 100 mg vitamin C drink, then fast for 3 hours.

A snack (plain yogurt and water) will be provided 1.5 hours after ingestion. A 24-hour dietary recall and semi-quantitative food frequency questionnaire (FFQ) will be conducted, with two additional 24-hour recalls by phone (2 weekdays and 1 weekend day).

Participants will then enter a 1-year equilibration period, recording illness and menstrual data monthly. The research team will monitor via LINE or email.

Visit 3 (Month 9; M9):

Collect fasting blood (5 mL) for Hb, glucose, HbA1c, and lipid profile; measure weight, BP, and conduct 24-hour recall (plus two by phone).

Visit 4 (After 1 year; WK0):

Collect fasting blood (10 mL) for Hb, SF, TfR, CRP, AGP, erythrocyte isotopic enrichment.

Measure weight, body composition, pregnancy test, and dietary recalls (3 days) and FFQ.

Visits 5-7 (WK8, WK16, WK24):

For eligible participants, repeat blood tests (7 mL) for Hb, SF, TfR, CRP, AGP, isotopic enrichment, anthropometry, pregnancy test, 3-day dietary recalls, and FFQ.

2.4 Research Instruments

  1. General information and medical history questionnaire, 24-hour dietary recall, and FFQ.

  2. Illness and menstrual record forms.

  3. Anthropometry and clinical measures:

    • Weight: InBody digital scale
    • Height: Harpenden stadiometer
    • Body composition: Bioelectrical Impedance Analyzer (BIA; InBody)
    • Blood pressure: Omron digital sphygmomanometer
  4. Laboratory analyses:

    • Hb: Complete Blood Count (CBC) using flow cytometry
    • SF, TfR, CRP, AGP: ELISA (SFa calculated from SF, CRP, AGP)
    • Hemoglobin typing: Capillary electrophoresis
    • Fasting glucose: Enzymatic method
    • HbA1c: Turbidimetric inhibition immunoassay
    • Lipids: Enzymatic colorimetric and homogeneous methods
    • Iron isotopes: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 2.5 Data Analysis Nutrient intake (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated using INMUCAL software.

Dietary patterns will be analyzed using Principal Component Analysis (PCA).

The average iron absorption (Fe_abs) over the study period will be calculated as:

Feabs=kabs×FetotalFe_{abs} = k_{abs} \times Fe_{total}Feabs=kabs×Fetotal where Fe_total is the total body iron at the midpoint estimated from the regression of Fe_total over time, and k_abs is the fractional iron absorption rate derived from the slope of the regression line of ln(⁵⁷Fe) vs. time.

Average iron loss (Fe_loss) is calculated similarly:

Feloss=kloss×FetotalFe_{loss} = k_{loss} \times Fe_{total}Feloss=kloss×Fetotal

Iron gain (Fe_gain) is calculated as:

Fegain=Feabs-FelossFe_{gain} = Fe_{abs} - Fe_{loss}Fegain=Feabs-Feloss Differences between groups in general characteristics, biochemical parameters, and iron absorption/loss slopes will be tested using Independent t-test or Mann-Whitney U-test, as appropriate.

A Linear Mixed-Effects Model will be used to analyze group differences in longitudinal changes of iron absorption, loss, and gain.

Statistical significance will be set at p < 0.05.

研究类型

观察性的

注册 (估计的)

64

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Aree Prachansuwan, Ph.D.
  • 电话号码:+66890060602

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

取样方法

非概率样本

研究人群

The study population will consist of 64 women aged 40-50 years, divided into two groups: 32 participants who are overweight or obese, and 32 participants with normal weight.

描述

Inclusion Criteria:

  • Normal weight group

    1. Aged 40-50 years
    2. Normal weight (BMI 18.5-22.9 kg/m²)
    3. Hb ≥12.0 g/dL and inflammation-adjusted SFa <50.0 µg/L
    4. CRP <5.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years
  • Overweight/obese group

    1. Aged 40-50 years
    2. Overweight or obese [Body Mass Index (BMI) ≥25.0 kg/m²] - the BMI cut-off follows the agreement of countries under the Coordinated Research Project (CRP) E43038 "Using the iron isotope dilution technique to assess the influence of inflammation on long-term iron absorption and loss," supported by the IAEA
    3. Hemoglobin (Hb) ≥12.0 g/dL and inflammation-adjusted serum ferritin (SFa) <50.0 µg/L
    4. C-reactive protein (CRP) between 5.0-25.0 mg/L
    5. Normal hemoglobin typing
    6. Plans to reside in the study area for >2 years

Exclusion Criteria:

  • Normal weight group

    1. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    2. Having metabolic NCDs (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    3. Pregnant, breastfeeding, or planning pregnancy during the study
    4. Chronic infectious disease (e.g., tuberculosis, AIDS)
    5. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    6. Taking vitamin or mineral supplements during or within two weeks prior to the study
    7. Participating in a weight-loss program
    8. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    9. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    10. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)
  • Overweight/obese group

    1. Obesity class II (BMI ≥35.0 kg/m²) with high health risk
    2. Having serious medical conditions such as cancer, chronic kidney disease, chronic liver disease, or chronic heart failure
    3. Having metabolic noncommunicable diseases (e.g., diabetes, hyperlipidemia, hypertension) requiring hospitalization
    4. Pregnant, breastfeeding, or planning pregnancy during the study
    5. Chronic infectious disease (e.g., tuberculosis, AIDS)
    6. Regular use of anti-inflammatory or other medications (except contraceptives and acne medication)
    7. Taking vitamin or mineral supplements during or within two weeks prior to the study
    8. Participating in a weight-loss program
    9. Known intolerance to iron supplements (e.g., vomiting, diarrhea, abdominal pain, bloating, nausea, or allergic reactions such as rash, breathing difficulty, chest tightness, facial or lip swelling)
    10. Blood transfusion, blood donation, or significant blood loss during the study or within 6 months before enrollment
    11. Heavy menstrual bleeding (>80 mL/day, calculated from menstrual record)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Normal weight

BMI 18.5-22.9 kg/m2

Overweight or obesity

BMI 25-35 kg/m2

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mean long-term iron absorption (Fe abs)
大体时间:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).

Calculated over the duration of the study as follows: Fe abs = k abs x Fe total Where Fe total is the total body iron at the midpoint, calculated from the linear regression of Fe total versus time across each measurement point; and k abs is the fraction of total body iron absorbed per unit of time (derived from the slope of the linear regression equation of ln 57 Fe versus time).

57 Fe isotope will be measured using Inductively Coupled Plasma Mass Spectrometry (ICP-MS).

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24).
Mean long-term iron loss (Fe loss)
大体时间:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated in the same manner as iron absorption: Fe loss = k loss x Fe total Where k loss is the fraction of total body iron lost per unit of time.

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Iron gain (Fe gain)
大体时间:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Calculated as net iron balance: Fe gain = Fe abs - Fe loss

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

次要结果测量

结果测量
措施说明
大体时间
Weight (kg)
大体时间:Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Weight will be measured in kg (to the nearest 0.1 kg) using an Inbody digital weighing scale.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Height (cm)
大体时间:Visit 1 (Screening)

Height will be measured to the mearest 0.1 cm using a Harpenden stadiometer.

Visit 1 (Screening)
Body Mass Index (BMI, kg/m²)
大体时间:Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

BMI will be calculatedn body weight in kilograms divided by height in meters squared.

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Body composition (fat mass)
大体时间:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Body composition (fat mass) will be measured using the Bioelectrical Impedance Analyzer (BIA; InBody).

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Nutrient intakes
大体时间:Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Nutrient intakes (energy, carbohydrate, protein, fat, iron, zinc, calcium, vitamin C, vitamin A, and fiber) will be calculated from 3-day 24-hr dietary recalls using INMUCAL software.

Visit 2 (Month 0), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Dietary pattern
大体时间:Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)

Dietary patern from FFQ will be analyzed using the Principal Component Analysis (PCA)

Visit 2 (Month 0), Visit 4 (after 1 year; WK0), Visits 7 (WK24)
Hemoglobin (Hb, g/L)
大体时间:Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

Hb concentration will be assessed using flow cytometry

Visit 1 (Screening), Visit 3 (Month 9), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Serum ferritin (SF, µg/L)
大体时间:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

SF will be measured using Enzyme-linked immunosorbent assay (ELISA)

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
serum transferrin receptor (sTfR µg/L)
大体时间:Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

sTfR will be assessed using ELISA

Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
c-reactive protein (CRP, mg/L)
大体时间:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

CRP will measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
alpha-1 acid glycoprotein (AGP, g/L)
大体时间:Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)

AGP will be measured using ELISA

Visit 1 (Screening), Visit 4 (after 1 year; WK0), Visits 5-7 (WK8, WK16, WK24)
Glycated hemoglobin (HbA1c, %)
大体时间:Visit 3 (Month 9)

HbA1c wil be measured by Turbidimetric inhibition immunoassay

Visit 3 (Month 9)
Lipid profile
大体时间:Visit 3 (Month 9)

Lipid profile (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) will be measured using Enzymatic colorimetric and homogeneous methods.

Visit 3 (Month 9)
Blood pressure (BP, mmHg)
大体时间:Visit 3 (Month 9)

BP will be measured using Omron digital sphygmomanometer

Visit 3 (Month 9)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Veronica LOPEZ TEROS, Ph.D.、Internation Atomic Energy Agency

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月8日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年8月31日

研究注册日期

首次提交

2026年8月6日

首先提交符合 QC 标准的

2026年9月28日

首次发布 (实际的)

2026年10月2日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

There has been ongoing discussion regarding collaboration on data analysis and publication among countries that have conducted studies supported by the International Atomic Energy Agency (IAEA).

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅